Strides Pharma Science shareholders approved all six resolutions tabled at the company’s 35th annual general meeting (AGM) held on August 14, 2026. The meeting, conducted via video conferencing, covered routine corporate governance matters including the adoption of audited financial statements for FY26 and declaration of a final dividend.

The scrutinizer’s report confirmed that all resolutions passed with requisite majority through remote e-voting and polling at the meeting. A total of 97,939 shareholders were on record as of the cutoff date, with significant participation from both promoter and public shareholders.

Voting Participation Overview

Promoter group engagement remained consistently high across all resolutions, with e-voting participation ranging between 95% and 100% of shares held. Public institutional investors also showed strong engagement, particularly on financial and dividend-related resolutions.

Key Resolutions Approved

Shareholders approved the adoption of audited consolidated financial statements for the financial year ended March 31, 2026, along with reports from the Board of Directors and statutory auditors. The resolution received overwhelming support with 6,73,88,862 votes in favour against just 220 votes against.

The final dividend declaration for FY26 was also approved as an ordinary resolution. This resolution saw even higher support, with 6,76,53,890 votes cast in favour and only 165 votes against.

Board Appointments

Three director-related resolutions were placed before shareholders:

• Re-appointment of retiring director Arun Kumar as an ordinary resolution
• Appointment of Mr. Aditya Arun Kumar as non-executive director
• Appointment of Mr. Venkata Seetharama Raju Pakalapati as executive director (special resolution)

All three appointments received majority approval. The re-appointment of Arun Kumar saw 6,50,04,913 votes in favour, while institutional shareholders registered 13,78,932 votes against. Aditya Arun Kumar’s appointment received 6,68,87,882 favourable votes, with 7,07,748 votes cast against.

Special Resolution on Director Compensation

A special resolution seeking approval for payment of commission to non-executive directors in the event of profit inadequacy was also passed. This resolution garnered 6,68,83,210 votes in favour against 1,79,999 votes against.

Joseph & Chacko LLP served as scrutinizer for the remote e-voting process, which ran from August 10 to August 13, 2026. KFin Technologies Limited provided the e-voting platform for shareholders.

Strides Pharma Science reported a consolidated profit after tax (PAT) of ₹1,655 million for Q1FY27, marking a 56.7% year-on-year increase. The bottom-line expansion was primarily driven by a one-time exceptional gain of ₹742.07 million from the dilution of its controlling stake in Pivot Path Private Limited, which contributed ₹534 million to PAT net of tax. Excluding this non-recurring item, operational PAT rose 8% to ₹1,231 million, demonstrating underlying resilience despite absorbing approximately ₹131 million in elevated freight and operating costs linked to geopolitical disruptions in the Middle East.

The unaudited financial results for the quarter ended June 30, 2026, were reviewed by the Audit Committee and approved by the Board of Directors on July 31, 2026. The Statutory Auditors carried out a limited review of the standalone and consolidated financial results, prepared in accordance with Ind AS. Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company published newspaper advertisements in 'Financial Express' and 'Lokmat' on August 1, 2026, providing an extract of the unaudited financial results. The full format of the quarterly financial results has been filed with the stock exchanges under Regulation 33 of the SEBI (LODR) Regulations, 2015.

Consolidated revenue from operations grew 13% year-on-year to ₹12,654 million. The growth was broad-based, with Ex-US markets delivering a robust 17% expansion to ₹5,875 million ($63 million), while the US business remained steady at ₹6,282 million ($68 million). Badree Komandur, Managing Director and Group CEO, attributed the performance to successful diversification strategies and strong execution in regulated markets across Europe, the UK, Nordics, and Africa.

Financial Performance Highlights

Gross margin expanded by 14% year-on-year to ₹7,702 million, improving the gross margin percentage by 60 basis points to 60.9%. This improvement was driven by a favorable business mix within Ex-US markets. However, EBITDA margin contracted slightly to 18.2% from 19.5% in Q1FY26, as absolute operating costs outpaced revenue growth. Vikesh Kumar, Group CFO, noted that employee costs held steady at 19.2% of revenue, while other operating costs increased by ₹29.0 million due to higher manufacturing expenses. Freight costs rose to 6.2% of revenue from 5.3% a year ago, an increase of ₹18.9 million.

The company reduced net debt by ₹119 million during the quarter, bringing closing net debt to ₹1,424.6 million and the Net Debt-to-EBITDA ratio to 1.52x. Operating cash flow stood at ₹1,087 million for the quarter, representing an EBITDA-to-cash conversion of 47%. CARE Ratings upgraded the company's Long-Term Bank Facilities rating to CARE A+; Stable from CARE A; Positive, reflecting improved creditworthiness.

Strategic Developments and Market Outlook

In the US market, Strides Pharma Science launched two new products in Q1FY27, bringing the total number of commercialized products to 72. The company continues to rank among the top three in 37 products, contributing approximately 70% of total US revenue. Management expects new product approvals in H2FY27 and aims for North America business revenue of ~$375 million by FY28. A key growth lever is the Controlled Substances portfolio, where quota allocations are expected to improve after demonstrating past sales history over 1.5 years. The company also filed a second Nasal Spray product in May 2026 and expects approval for the first nasal spray filing in H2FY27.

Ex-US markets contributed significantly to growth, with strong customer advocacy enabling expansion in the UK and Nordics. Africa operations delivered stellar growth through the Brands business. While Ex-US revenue was lower sequentially compared to Q4FY26 due to temporary supply chain disruptions and shipment delays, management views this as a timing issue rather than a demand issue, expecting recovery in subsequent quarters.

What the Numbers Show

The divergence between 13% revenue growth and 5.40% EBITDA growth highlights the impact of macroeconomic pressures on operating efficiency. While gross margins expanded, indicating better product mix or pricing power, the compression in EBITDA margins suggests that selling, general, and administrative expenses or direct operational costs are rising faster than revenue. The strong 17% growth in Ex-US markets serves as a critical counterbalance to the steady US business, validating the company's diversification strategy. The reduction in net debt alongside healthy operational cash flows demonstrates prudent balance sheet management, positioning the company to withstand further geopolitical volatility. Additionally, the EcoVadis sustainability score improved to 68/100, a 19-point increase over the previous year.